key: cord-0937374-gkjgyyyf
authors: Fernández, Pehuén; Alaye, María Luján; Chiple, María Emilia García; Arteaga, Javier De; Douthat, Walter; Fuente, Jorge De La; Chiurchiu, Carlos
title: Glomerulopathies after vaccination against COVID-19. Four cases with three different vaccines in Argentina
date: 2021-09-25
journal: Nefrologia
DOI: 10.1016/j.nefro.2021.09.003
sha: 35cc87961817f9b155a7922d363de1332da7c03d
doc_id: 937374
cord_uid: gkjgyyyf

nan

w w w . r e v i s t a n e f r o l o g i a . c o m

Letter to the Editor Glomerulopathies after vaccination against COVID-19. Four cases with three different vaccines in Argentina Glomerulopatías después de la vacunación frente a COVID-19. Cuatro casos con tres vacunas diferentes en Argentina

After reading some recent reports on the appearance or de novo recurrence of different glomerulopathies after the application of vaccines against COVID-19 1-10 we would like to contribute our experience.

Four patients (P) previously asymptomatic began with asthenia (P1, P2), foamy urine (all) and edema (P2, P3) within 2 weeks after the first dose of the COVID-19 vaccine (P1: Sinopharm, P2: Oxford-AstraZeneca, P3 and P4: Gamaleya). All presented hypertension and microscopic hematuria. The first three patients also presented with acute kidney injury, nephrotic range proteinuria, hypoalbuminemia and dyslipidemia. The P4 increased his proteinuria significantly. Renal biopsies performed showed two IgA nephropathy with crescent ( Supplementary Fig. S1 , A-F) and recurrence of proliferative glomerulonephritis ( Supplementary Fig. S2 , A and B). S2 , C and D) and it was interpreted as the beginning of a recurrence of her disease. All received corticosteroids and P1 and P2 also received cyclophosphamide. P1, P2 and P3 presented partial remission and P4 complete remission (Table 1) .

Although it is very difficult to prove causation, at the time of this letter there are at least 40 reports of different types of glomerulopathies after receiving the COVID-19 vaccine from different manufacturers (Pfizer, Moderna, AstraZeneca and Sinovac). 1-10 To our knowledge, our reports would be the first related to the Sputnik V (Gamaleya) and BBIBP-CorV (Sinopharm) vaccines. Undoubtedly, the benefits of vaccines far outweigh the risks, but these findings emphasize the importance of surveillance in patients with previous glomerulonephritis and/or the appearance of foamy urine, edemas, hypertension or laboratory abnormalities. 

This work has not received any type of funding.

De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far?

IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine

Letter regarding: "a case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination

Nephrotic syndrome following ChAdOx1 nCoV-19 vaccine against SARScoV-2

Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine

Membranous nephropathy following anti-Covid-19 mRNA vaccination

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: Casuality or causality?

Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination

Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine

A case of membranous nephropathy following Pfizer-BioNTech mRNA vaccine against coronavirus 2019

The author declares that he has no conflict of interest.

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.nefro.2021.09.003. r e f e r e n c e s